Status: Finalised First registered on: 19/05/2014
Last updated on: 17/03/2015
1. Study identification
EU PAS Register NumberEUPAS6573
Official titleReal-life effectiveness evaluation of the long-acting muscarinic antagonist aclidinium bromide (Eklira®) for the management of COPD in a routine UK primary care population - Study 1
Study title acronymReal-life acceptability of Eklira
Study typeObservational study
Brief description of the studyTo evaluate the real-life effectiveness of the antimuscarine bronchodilator aclidinium bromide (Eklira®) in three combined studies following the launch of Eklira® in the UK. This first study involves characterising patients prescribed aclidinium bromide from tiotropium, and determining how many patients are satisfied with their change to aclidinium therapy. This will determine the acceptability of aclidinium in clinical practice.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsRIRL
Department/Research group
Organisation/affiliationResearch in Real Life Ltd.
Website/Homepagewww.rirl.org
Details of (Primary) lead investigator
Title Dr
Last name Daina
First name Lim
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)

Countries in which this study is being conducted
National study

United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed26/09/201326/09/2013
Start date of data collection01/10/201301/10/2013
Start date of data analysis02/06/201413/05/2014
Date of interim report, if expected
Date of final study report29/08/201406/10/2014
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesAlmirall50
Charities
Government body
Research councils
EU funding scheme
OtherResearch in Real Life50
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Price
First name David
Address line 1University of Aberdeen
Address line 2 
Address line 3 
CityAberdeen 
PostcodeAB24 3FX 
CountryUnited Kingdom
Phone number (incl. country code)441223967855 
Alternative phone number 
Fax number (incl. country code) 
Email address david@rirl.org
Public Enquiries
Title Professor 
Last name Price 
First name David 
Address line 1University of Aberdeen 
Address line 2 
Address line 3 
CityAberdeen 
PostcodeAB24 3FX 
CountryUnited Kingdom 
Phone number (incl. country code)441223967855 
Alternative phone number 
Fax number (incl. country code) 
Email address david@rirl.org 
Top